Parkin and mitophagy in cancer

Oncogene

Volumn 36, Issue 10, 2017, Pages 1315-1327

  Bernardini, J P ^a,b   Lazarou, M ^c   Dewson, G ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PARKIN; PINK1 PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; BIOENERGY; CELL CYCLE; CELL PROLIFERATION; CELL TRANSPORT; COLORECTAL CANCER; HOMEOSTASIS; HUMAN; LUNG CANCER; MALIGNANT NEOPLASM; MELANOMA; METABOLISM; MITOCHONDRION; MITOPHAGY; NECROPTOSIS; ONCOGENE K RAS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UBIQUITINATION; ANIMAL; ENERGY METABOLISM; ENZYME SPECIFICITY; GENETICS; NEOPLASM;

ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; NEOPLASMS; PROTEIN KINASES; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 85028248780     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.302     Document Type: Review

References (205)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
2. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1: 1269.
3. Cleeter MW, Cooper JM, Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992; 58: 786-789.
4. Sershen H, Mason MF, Hashim A, Lajtha A. Effect of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum. Eur J Pharmacol 1985; 113: 135-136.
5. Wagner GC, Jarvis MF, Carelli RM. Ascorbic acid reduces the dopamine depletion induced by MPTP. Neuropharmacology 1985; 24: 1261-1262.
6. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
7. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
8. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
9. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Investig 2009; 119: 650-660.
10. Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N, Mizuno Y et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 2005; 14: 71-84.
11. Lucking CB, Abbas N, Durr A, Bonifati V, Bonnet AM, de Broucker T et al. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet 1998; 352: 1355-1356.
12. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 1998; 44: 935-941.
13. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-1p36. Am J Hum Genet 2001; 68: 895-900.
14. Hatano Y, Sato K, Elibol B, Yoshino H, Yamamura Y, Bonifati V et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004; 63: 1482-1485.
15. Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 2004; 56: 424-427.
16. Kim SY, Seong MW, Jeon BS, Kim SY, Ko HS, Kim JY et al. Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease. Clin Genet 2012; 82: 77-82.
17. Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75: 1189-1194.
18. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003; 60: 796-801.
19. Hedrich K, Hagenah J, Djarmati A, Hiller A, Lohnau T, Lasek K et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006; 63: 833-838.
20. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005; 102: 2174-2179.
21. Pickrell AM, Huang CH, Kennedy SR, Ordureau A, Sideris DP, Hoekstra JG et al. Endogenous parkin preserves dopaminergic substantia nigral neurons following mitochondrial DNA mutagenic stress. Neuron 2015; 87: 371-381.
22. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008; 27: 6002-6011.
23. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci USA 2011; 108: 16259-16264.
24. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69: 1542-1550.
25. Xu L, Lin DC, Yin D, Koeffler HP. An emerging role of PARK2 in cancer. J Mol Med 2014; 92: 31-42.
26. Saito S, Sirahama S, Matsushima M, Suzuki M, Sagae S, Kudo R et al. Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27. Cancer Res 1996; 56: 5586-5589.
27. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-6q27. Proc Natl Acad Sci USA 2003; 100: 5956-5961.
28. Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 2003; 22: 8370-8378.
29. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosom Cancer 2003; 38: 40-52.
30. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 2000; 19: 1572-1578.
31. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 2004; 10: 2720-2724.
32. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005; 92: 201-205.
33. Watson RO, Manzanillo PS, Cox JS. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012; 150: 803-815.
34. Bento CF, Empadinhas N, Mendes V. Autophagy in the fight against tuberculosis. DNA Cell Biol 2015; 34: 228-242.
35. Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS et al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature 2013; 501: 512-516.
36. Lazarou M. Keeping the immune system in check: a role for mitophagy. Immunol Cell Biol 2015; 93: 3-10.
37. Lazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 2015; 524: 309-314.
38. Richter B, Sliter DA, Herhaus L, Stolz A, Wang C, Beli P et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc Natl Acad Sci USA 2016; 113: 4039-4044.
39. Chen Y, Dorn GW 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 2013; 340: 471-475.
40. Gong G, Song M, Csordas G, Kelly DP, Matkovich SJ, Dorn GW 2nd. Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation in mice. Science 2015; 350: aad2459.
41. Durcan TM, Fon EA. The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev 2015; 29: 989-999.
42. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 2015; 85: 257-273.
43. Trempe JF, Fon EA. Structure and function of Parkin, PINK1, and DJ-1, the three musketeers of neuroprotection. Front Neurol 2013; 4: 38.
44. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci 2014; 37: 315-324.
45. Meissner C, Lorenz H, Weihofen A, Selkoe DJ, Lemberg MK. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J Neurochem 2011; 117: 856-867.
46. Deas E, Plun-Favreau H, Gandhi S, Desmond H, Kjaer S, Loh SH et al. PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum Mol Genet 2011; 20: 867-879.
47. Whitworth AJ, Lee JR, Ho VM, Flick R, Chowdhury R, McQuibban GA. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Dis Models Mech 2008; 1: 168-174 discussion 173.
48. Yamano K, Youle RJ. PINK1 is degraded through the N-end rule pathway. Autophagy 2013; 9: 1758-1769.
49. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 2010; 191: 933-942.
50. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 2010; 107: 378-383.
51. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 2010; 189: 211-221.
52. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010; 8: e1000298.
53. Jin SM, Youle RJ. The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria. Autphagy 2013; 9: 1750-1757.
54. Lazarou M, Jin SM, Kane LA, Youle RJ. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. Dev Cell 2012; 22: 320-333.
55. Okatsu K, Uno M, Koyano F, Go E, Kimura M, Oka T et al. A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment. J Biol Chem 2013; 288: 36372-36384.
56. Riley BE, Lougheed JC, Callaway K, Velasquez M, Brecht E, Nguyen L et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun 2013; 4: 1982.
57. Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, Gourlay R et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol 2012; 2: 120080.
58. Trempe JF, Sauve V, Grenier K, Seirafi M, Tang MY, Menade M et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 2013; 340: 1451-1455.
59. 2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. J Biol Chem 2009; 284: 14978-14986.
60. Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K et al. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J 2014; 460: 127-139.
61. Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 2013; 496: 372-376.
62. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL et al. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum Mol Genet 2011; 20: 1726-1737.
63. Ziviani E, Tao RN, Whitworth AJ. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci USA 2010; 107: 5018-5023.
64. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-1166.
65. Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 2014; 205: 143-153.
66. Kazlauskaite A, Martinez-Torres RJ, Wilkie S, Kumar A, Peltier J, Gonzalez A et al. Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation. EMBO Rep 2015; 16: 939-954.
67. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 2014; 510: 162-166.
68. Ordureau A, Sarraf SA, Duda DM, Heo JM, Jedrychowski MP, Sviderskiy VO et al. Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol Cell 2014; 56: 360-375.
69. Ordureau A, Heo JM, Duda DM, Paulo JA, Olszewski JL, Yanishevski D et al. Defining roles of PARKIN and ubiquitin phosphorylation by PINK1 in mitochondrial quality control using a ubiquitin replacement strategy. Proc Natl Acad Sci USA 2015; 112: 6637-6642.
70. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012; 81: 203-229.
71. Cornelissen T, Haddad D, Wauters F, Van Humbeeck C, Mandemakers W, Koentjoro B et al. The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. Hum Mol Genet 2014; 23: 5227-5242.
72. Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 2014; 510: 370-375.
73. Cunningham CN, Baughman JM, Phu L, Tea JS, Yu C, Coons M et al. USP30 and parkin homeostatically regulate atypical ubiquitin chains on mitochondria. Nat Cell Biol 2015; 17: 160-169.
74. Liang JR, Martinez A, Lane JD, Mayor U, Clague MJ, Urbe S. USP30 deubiquity-lates mitochondrial Parkin substrates and restricts apoptotic cell death. EMBO Rep 2015; 16: 618-627.
75. Durcan TM, Tang MY, Perusse JR, Dashti EA, Aguileta MA, McLelland GL et al. USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. EMBO J 2014; 33: 2473-2491.
76. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12: 119-131.
77. Narendra D, Kane LA, Hauser DN, Fearnley IM, Youle RJ. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 2010; 6: 1090-1106.
78. Wong YC, Holzbaur EL. Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation. Proc Natl Acad Sci USA 2014; 111: E4439-E4448.
79. Heo JM, Ordureau A, Paulo JA, Rinehart J, Harper JW. The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy. Mol Cell 2015; 60: 7-20.
80. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 2004; 117: 2805-2812.
81. Kataoka T, Holler N, Micheau O, Martinon F, Tinel A, Hofmann K et al. Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via its unique C-terminal extension. J Biol Chem 2001; 276: 19548-19554.
82. Murakawa T, Yamaguchi O, Hashimoto A, Hikoso S, Takeda T, Oka T et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat Commun 2015; 6: 7527.
83. Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis complex. Nat Rev Mol Cell Biol 2013; 14: 759-774.
84. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 1991; 266: 17707-17712.
85. Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. Front Oncol 2013; 3: 292.
86. Novak I, Kirkin V, McEwan DG, Zhang J, Wild P, Rozenknop A et al. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep 2010; 11: 45-51.
87. Schwarten M, Mohrluder J, Ma P, Stoldt M, Thielmann Y, Stangler T et al. Nix directly binds to GABARAP: a possible crosstalk between apoptosis and autophagy. Autophagy 2009; 5: 690-698.
88. Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S, Gustafsson AB. Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J Biol Chem 2012; 287: 19094-19104.
89. Ray R, Chen G, Vande Velde C, Cizeau J, Park JH, Reed JC et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 2000; 275: 1439-1448.
90. Zhu Y, Massen S, Terenzio M, Lang V, Chen-Lindner S, Eils R et al. Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determines pro-survival mitophagy versus apoptosis. J Biol Chem 2013; 288: 1099-1113.
91. Liu L, Feng D, Chen G, Chen M, Zheng Q, Song P et al. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat Cell Biol 2012; 14: 177-185.
92. Wu W, Tian W, Hu Z, Chen G, Huang L, Li W et al. ULK1 translocates to mitochondria and phosphorylates FUNDC1 to regulate mitophagy. EMBO Rep 2014; 15: 566-575.
93. Chen G, Han Z, Feng D, Chen Y, Chen L, Wu H et al. A regulatory signaling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. Mol Cell 2014; 54: 362-377.
94. Liu L, Sakakibara K, Chen Q, Okamoto K. Receptor-mediated mitophagy in yeast and mammalian systems. Cell Res 2014; 24: 787-795.
95. Wu H, Xue D, Chen G, Han Z, Huang L, Zhu C et al. The BCL2L1 and PGAM5 axis defines hypoxia-induced receptor-mediated mitophagy. Autophagy 2014; 10: 1712-1725.
96. Lu W, Karuppagounder SS, Springer DA, Allen MD, Zheng L, Chao B et al. Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder. Nat Commun 2014; 5: 4930.
97. Lo SC, Hannink M. PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. J Biol Chem 2006; 281: 37893-37903.
98. Wang Z, Jiang H, Chen S, Du F, Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 2012; 148: 228-243.
99. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443-453.
100. Yun J, Puri R, Yang H, Lizzio MA, Wu C, Sheng ZH et al. MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin. eLife 2014; 3: e01958.
101. Fu M, St-Pierre P, Shankar J, Wang PT, Joshi B, Nabi IR. Regulation of mitophagy by the Gp78 E3 ubiquitin ligase. Mol Biol Cell 2013; 24: 1153-1162.
102. Orvedahl A, Sumpter Jr R, Xiao G, Ng A, Zou Z, Tang Y et al. Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature 2011; 480: 113-117.
103. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science 2014; 345: 1250256.
104. Li MX, Dewson G. Mitochondria and apoptosis: emerging concepts. F1000Prime Rep 2015; 7: 42.
105. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
106. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
107. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-241.
108. Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. Embo J 2007; 26: 2527-2539.
109. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122: 927-939.
110. Lindqvist LM, Heinlein M, Huang DC, Vaux DL. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. Proc Natl Acad Sci USA 2014; 111: 8512-8517.
111. Hollville E, Carroll RG, Cullen SP, Martin SJ. Bcl-2 family proteins participate in mitochondrial quality control by regulating Parkin/PINK1-dependent mitophagy. Mol Cell 2014; 55: 451-466.
112. Carroll RG, Hollville E, Martin SJ. Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1. Cell Rep 2014; 9: 1538-1553.
113. Johnson BN, Berger AK, Cortese GP, Lavoie MJ. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci USA 2012; 109: 6283-6288.
114. Charan RA, Johnson BN, Zaganelli S, Nardozzi JD, LaVoie MJ. Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin. Cell Death Dis 2014; 5: e1313.
115. Chen D, Gao F, Li B, Wang H, Xu Y, Zhu C et al. Parkin mono-ubiquitinates Bcl-2 and regulates autophagy. J Biol Chem 2010; 285: 38214-38223.
116. Zhang C, Lee S, Peng Y, Bunker E, Giaime E, Shen J et al. PINK1 triggers autocatalytic activation of Parkin to specify cell fate decisions. Curr Biol 2014; 24: 1854-1865.
117. Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998; 187: 1477-1485.
118. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
119. Radogna F, Cerella C, Gaigneaux A, Christov C, Dicato M, Diederich M. Cell type-dependent ROS and mitophagy response leads to apoptosis or necroptosis in neuroblastoma. Oncogene 2015; 35: 2839-2853.
120. Xia M, Meng G, Jiang A, Chen A, Dahlhaus M, Gonzalez P et al. Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus. Oncotarget 2014; 5: 3907-3918.
121. Tait SW, Oberst A, Quarato G, Milasta S, Haller M, Wang R et al. Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep 2013; 5: 878-885.
122. Remijsen Q, Goossens V, Grootjans S, Van den Haute C, Vanlangenakker N, Dondelinger Y et al. Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis 2014; 5: e1004.
123. Lu W, Sun J, Yoon JS, Zhang Y, Zheng L, Murphy E et al. Mitochondrial protein PGAM5 regulates mitophagic protection against cell necroptosis. PLoS One 2016; 11: e0147792.
124. Okatsu K, Saisho K, Shimanuki M, Nakada K, Shitara H, Sou YS et al. p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells 2010; 15: 887-900.
125. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 2007; 8: 870-879.
126. Otera H, Mihara K. Molecular mechanisms and physiologic functions of mitochondrial dynamics. J Biochem 2011; 149: 241-251.
127. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet 2010; 19: 4861-4870.
128. Poole AC, Thomas RE, Yu S, Vincow ES, Pallanck L. The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. PLoS One 2010; 5: e10054.
129. Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J Cell Biol 2010; 191: 1367-1380.
130. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008; 27: 433-446.
131. Wang H, Song P, Du L, Tian W, Yue W, Liu M et al. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease. J Biol Chem 2011; 286: 11649-11658.
132. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011; 147: 893-906.
133. Birsa N, Norkett R, Wauer T, Mevissen TE, Wu HC, Foltynie T et al. Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase. J Biol Chem 2014; 289: 14569-14582.
134. Fransson S, Ruusala A, Aspenstrom P. The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking. Biochem Biophys Res Commun 2006; 344: 500-510.
135. Landes T, Emorine LJ, Courilleau D, Rojo M, Belenguer P, Arnaune-Pelloquin L. The BH3-only Bnip3 binds to the dynamin Opa1 to promote mitochondrial fragmentation and apoptosis by distinct mechanisms. EMBO Rep 2010; 11: 459-465.
136. Quinsay MN, Lee Y, Rikka S, Sayen MR, Molkentin JD, Gottlieb RA et al. Bnip3 mediates permeabilization of mitochondria and release of cytochrome c via a novel mechanism. J Mol Cell Cardiol 2010; 48: 1146-1156.
137. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003; 37: 735-749.
138. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010; 42: 77-82.
139. Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet 2014; 46: 588-594.
140. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci: Off J Soc Neurosci 2005; 25: 7968-7978.
141. da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009; 11: 1370-1375.
142. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004; 279: 18614-18622.
143. Kim KY, Stevens MV, Akter MH, Rusk SE, Huang RJ, Cohen A et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Investig 2011; 121: 3701-3712.
144. Liu K, Li F, Han H, Chen Y, Mao Z, Luo J et al. Parkin regulates the activity of pyruvate kinase M2. J Biol Chem 2016; 291: 10307-10317.
145. Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat Rev Cancer 2014; 14: 709-721.
146. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012; 12: 685-698.
147. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38-44.
148. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003; 12: 2277-2291.
149. Hyun DH, Lee M, Hattori N, Kubo S, Mizuno Y, Halliwell B et al. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002; 277: 28572-28577.
150. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-519.
151. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008; 28: 718-731.
152. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009; 19: 12-16.
153. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23: 537-548.
154. Kuroda Y, Mitsui T, Kunishige M, Shono M, Akaike M, Azuma H et al. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 2006; 15: 883-895.
155. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352-1355.
156. Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013; 494: 492-496.
157. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW. Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet 2010; 6: e1001257.
158. Morris LG, Veeriah S, Chan TA. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 2010; 29: 3453-3464.
159. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 2010; 107: 15145-15150.
160. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956-2962.
161. Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J et al. Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle 2006; 5: 783-791.
162. Viotti J, Duplan E, Caillava C, Condat J, Goiran T, Giordano C et al. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Oncogene 2014; 33: 1764-1775.
163. Lee KS, Wu Z, Song Y, Mitra SS, Feroze AH, Cheshier SH et al. Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway. Genes Dev 2013; 27: 2642-2647.
164. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45: 279-284.
165. West AB, Kapatos G, O'Farrell C, Gonzalez-de-Chavez F, Chiu K, Farrer MJ et al. N-myc regulates parkin expression. J Biol Chem 2004; 279: 28896-28902.
166. Strieder V, Lutz W. Regulation of N-myc expression in development and disease. Cancer Lett 2002; 180: 107-119.
167. Wang M, Suzuki T, Kitada T, Asakawa S, Minoshima S, Shimizu N et al. Developmental changes in the expression of parkin and UbcR7, a parkin-interacting and ubiquitin-conjugating enzyme, in rat brain. J Neurochem 2001; 77: 1561-1568.
168. Kitada T, Asakawa S, Minoshima S, Mizuno Y, Shimizu N. Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm Genome: Off J Int Mamm Genome Soc 2000; 11: 417-421.
169. Kaminskyy VO, Piskunova T, Zborovskaya IB, Tchevkina EM, Zhivotovsky B. Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and-independent apoptosis by stimulating ROS formation. Autophagy 2012; 8: 1032-1044.
170. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5: 3056.
171. Thomas KJ, Jacobson MR. Defects in mitochondrial fission protein dynamin-related protein 1 are linked to apoptotic resistance and autophagy in a lung cancer model. PLoS One 2012; 7: e45319.
172. Hung JY, Hsu YL, Li CT, Ko YC, Ni WC, Huang MS et al. 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells. J Agric Food Chem 2009; 57: 9809-9816.
173. Dasgupta S, Soudry E, Mukhopadhyay N, Shao C, Yee J, Lam S et al. Mitochon-drial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol 2012; 227: 2451-2460.
174. Noviello C, Courjal F, Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 1996; 2: 1601-1606.
175. Orphanos V, McGown G, Hey Y, Boyle JM, Santibanez-Koref M. Proximal 6q, a region showing allele loss in primary breast cancer. Br J Cancer 1995; 71: 290-293.
176. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
177. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996; 69: 247-253.
178. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57: 353-361.
179. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127-2133.
180. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
181. Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Investig 2013; 123: 1068-1081.
182. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 2010; 9: 3534-3551.
183. Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle 2011; 10: 4065-4073.
184. Chourasia AH, Tracy K, Frankenberger C, Boland ML, Sharifi MN, Drake LE et al. Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Rep 2015; 16: 1145-1163.
185. Shen Y, Li DD, Wang LL, Deng R, Zhu XF. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy 2008; 4: 1067-1068.
186. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther 2011; 10: 1385-1393.
187. Kandala PK, Srivastava SK. Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget 2012; 3: 435-449.
188. Chourasia AH, Boland ML, Macleod KF. Mitophagy and cancer. Cancer Metab 2015; 3: 4.
189. Lai J, Flanagan J, Phillips WA, Chenevix-Trench G, Arnold J. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer. Br J Cancer 2003; 88: 270-276.
190. Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F et al. Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFkappaB activation in the tumor stroma. Cell Cycle 2012; 11: 4152-4166.
191. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011; 6: e18064.
192. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995; 310: 1500-1501.
193. Zanchetta LM, Garcia A, Lyng F, Walsh J, Murphy JE. Mitophagy and mitochondrial morphology in human melanoma-derived cells post exposure to simulated sunlight. Int J Radiat Biol 2011; 87: 506-517.
194. Christensen C, Bartkova J, Mistrik M, Hall A, Lange MK, Ralfkiaer U et al. A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility. Nat Commun 2014; 5: 5348.
195. Maes H, Agostinis P. Autophagy and mitophagy interplay in melanoma progression. Mitochondrion 2014; 19 Pt A: 58-68.
196. Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X et al. Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem 2012; 287: 30664-30676.
197. Sheen JH, Zoncu R, Kim D, Sabatini DM. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 2011; 19: 613-628.
198. Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 2009; 16: 103-114.
199. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One 2013; 8: e55096.
200. Maes H, Van Eygen S, Krysko DV, Vandenabeele P, Nys K, Rillaerts K et al. BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton. Cell Death Dis 2014; 5: e1127.
201. Hu HH, Kannengiesser C, Lesage S, Andre J, Mourah S, Michel L et al. PARKIN inactivation links Parkinson's disease to melanoma. J Natl Cancer Inst 2016; 108: djv340.
202. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27: 1447-1461.
203. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504: 296-300.
204. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015; 350: 1391-1396.
205. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.